Thu, May 30, 2024
Wed, May 29, 2024
Tue, May 28, 2024
Fri, May 24, 2024

Eliana Merle Maintained (BBIO) at Strong Buy with Decreased Target to $47 on, May 28th, 2024


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-47-on-may-28th-2024.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Eliana Merle of UBS, Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Decreased Target from $51 to $47 on, May 28th, 2024.

Eliana has made no other calls on BBIO in the last 4 months.



There are 6 other peers that have a rating on BBIO. Out of the 6 peers that are also analyzing BBIO, 1 agrees with Eliana's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Kostas Biliouris of "BMO Capital" Initiated at Hold and Held Target at $37 on, Wednesday, January 31st, 2024


These are the ratings of the 5 analyists that currently disagree with Eliana


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $43 on, Monday, May 20th, 2024
  • Cory Kasimov of "Evercore ISI Group" Initiated at Buy and Held Target at $50 on, Tuesday, May 14th, 2024
  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $45 on, Wednesday, March 20th, 2024
  • Salim Syed of "Mizuho" Maintained at Strong Buy with Decreased Target to $53 on, Tuesday, March 5th, 2024
  • David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $46 on, Friday, February 23rd, 2024

Publication Contributing Sources